Pharmacological modulation of the transient receptor potential melastatin type 8 (TRPM8) is currently under investigation as a new approach mainly for the treatment of pain. In this study, a series of N-substituted tryptamines was prepared to explore the structural requirements determining TRPM8 modulation. As a result of a fluorescence-based screening assay, we identified two compounds acting as an activator (2-(1H-indol-3-yl)-N-(4-phenoxybenzyl) ethanamine, compound 21) or an inhibitor (N,N-dibenzyl-2-(1H-indol-3-yl) ethanamine, compound 12) of calcium influx in HEK293 cells. In patch-clamp recordings, compound 21 displayed a significantly higher potency (EC 50 = 40±4 µM) and a similar efficacy when compared to menthol; by contrast, compound 12 produced a concentrationdependent inhibition of menthol-induced TRPM8 currents (IC 50 = 367±24 nM). Molecular modelling studies using a homology model of a single TRPM8 subunit identified a putative binding site located between the VSD and the TRP box, disclosing two different binding modes for the agonist and the antagonist.
Introduction
Transient receptor potential melastatin type-8 (TRPM8) is a transmembrane, non-selective Ca 2+ permeable cation channel, 1 considered as the major sensor for peripheral innocuous cool and its modulation contributes to a wide range of physiological and pathophysiological processes. One of the most investigated effects produced by TRPM8 modulation is the analgesia against chronic and neuropathic pain: in fact, it has been reported that peripheral and central activation of TRPM8 induces analgesia, specifically reversing the sensitization of the behavioral reflexes elicited by peripheral nerve injury. 2 Notably, both TRPM8 agonists and antagonists exert analgesic effects: in particular, while TRPM8 agonists produce profound analgesia 2 at very low concentrations, even greater effects have been reported for TRPM8 antagonists. 3 This analgesia modulation represents a novel approach in a largely unmet therapeutic need. 4 Moreover, many studies have recently revealed novel potential pharmacological implications for TRPM8 modulators. For example, TRPM8 agonists have been proposed as useful diagnostic and therapeutic tools for the treatment of prostate cancer and benign prostate hyperplasia (BPH). 5, 6 In fact the activation of TRPM8 receptors enhances apoptosis in prostate carcinoma cells, highlighting a potential involvement of this channel in androgen-responsive prostate cancer cell growth. Apart from androgen-sensitive prostate cancer, TRPM8 is abnormally over-expressed in other tumor malignancies, like breast cancer, 7, 8 human pancreatic adenocarcinoma,
Scheme 1. Synthesis of the N, 2-substituted indolethanamine derivatives 4-12
Nucleophilic displacement of the bromine atom of 1, 2 and 3 by different commercially available amines was performed in THF/TEA using palladium acetate as a catalyst. Under microwave conditions the final compounds 4-12 were obtained in 55-75% yield.
A different strategy was used for the synthesis of compounds 14-22, which employed tryptamine 13 as starting material (Scheme 2). Compound 14 was obtained as racemic mixture by nucleophilic substitution reaction of the tosyl derivative of the (1,2,3,4-tetrahydronaphthalen-4-yl)methanol (VI) with tryptamine (13) . This intermediate VI has been synthesized by reducing the 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid with lithium aluminium hydride, followed by tosylation with 4-methylbenzene-1-sulfonyl chloride (see supplementary information, scheme S1). 28 Reductive amination of different commercially available aldehydes with the tryptamine, using sodium triacetoxyborohydride as reductive agent gave the final compounds 15-21 in 51% -85% yields (Scheme 2). 21 Finally, treatment of derivative 21 with methyl iodide using NaH as a base allowed us to obtained the dimethyl derivative 22 in 37% yield.
Scheme 2. Synthesis of the N, 2-substituted indolethanamine derivatives 14-22
Screening of the activity of the synthesized compounds by Ca
2+ -imaging experiments
To investigate the potential agonistic or antagonistic properties on TRPM8 channels, all synthesized compounds were tested at three different concentrations (0.5, 5 and 50 M) by in vitro Ca 2+ fluorometric assays experiments using Fluo4-NW in HEK293 cells stably expressing mouse TRPM8 channels. The results obtained are normalized to the effects prompted by 100 M of the canonical agonist menthol 29 or by 10 M of the TRPM8 antagonist AMTB + 100 M menthol, 11 whose effects were reported as + 100% (activation) or -100% (inhibition), respectively (Figures 1A and 1B).
As reported in Figure 1A , compounds 4 and 5 showed agonist activity at high concentration (50 M), being about 2-fold more effective than menthol. At the same concentration, the presence of the sterically hindered biphenyl ethyl group on the amine moiety (6), led to slight loss of efficacy in comparison to 4 and 5, maintaining an efficacy similar to menthol. Interestingly, introduction of a sterically hindered group at N-1 indole position, such as a biphenyl methyl group, together with increased flexibility of the substituent on the amine moiety (7 versus 4 or 5) maintained agonistic efficacy .
The non-substituted N-1 indole derivatives (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) were quite productive. A direct linkage of the amine moiety with different bulky aromatic groups, such as naphthalene and quinolines, gives compounds 8-11 unable to act as TRPM8 modulators ( Figures 1A and 1B) . By contrast, the tertiary amine obtained by derivatization of tryptamine with a benzyl moiety (12) proved to be an effective and potent antagonist. Introduction of a methylene spacer between amine group and bulky aryl moiety in 8 led to the potent agonist 15, which showed to be 3-fold more effective than menthol at 50 M.
Introduction of substituents at position 2 of naphthalene ring, such as OMe (16) and OH (17) induced a shift from agonist to antagonistic activity for these derivatives at high concentration ( Fig. 1 B) . A similar effect was observed when the bicyclic system modification involves changes in the electronic nature of the ring (14) or an increase in ring size (18) . In addition, tryptamine benzyl derivatives 19 and 20 lost the agonistic activity shown by the methylated analogue 4.
Notably, compound 21 bearing a p-methoxybenzyl group showed significant agonist activity at 0.5 M, with a similar efficacy to that of menthol. At 50 M, the efficacy of derivative 21 was nearly 3-fold higher than that of menthol. Conversion of this compound to its N-methyl-2-(1-methyl-1H-indol-3-yl)-derivative (22) shifted the agonistic activity to antagonism, with an efficacy comparable to that of derivative 12, at all tested concentrations ( Figure 1B ). To investigate the ability of newly-described TRPM8 modulators to interfere with the activity of other TRP channels, particularly TRPV1 and TRPA1, two TRPM8 antagonist (12, 22) and one agonist (21) , were also tested in calcium fluorometric experiments in SH-SY5Y cells stably expressing mouse TRPV1 channels and in IMR90 cells natively expressing mouse TRPA1 channels. In this experiment the canonical TRPV1 agonist (capsaicin, 10 M) or antagonist (ruthenium red, 10 M) as well as the canonical TRPA1 agonist (AITC, 500 M) or antagonist (ruthenium red, 10 M) were used as controls. The values obtained for the tested compounds were normalized to the effects exerted by canonical agonists or agonist + antagonist co-exposure.
As reported in Figure 2 , compound 12 appeared a rather selective TRPM8 antagonist, showing weak activity on TRPV1 only at the highest concentration (Figure 2A ), and unremarkable activity on TRPA1 at all concentrations ( Figure 2B) 
Pharmacological properties of derivatives 21 and 12 characterized by patch-clamp electrophysiology
The previously described multicellular functional assay identified derivatives 21 and 12 as the most effective and potent agonist and antagonist compounds, respectively, on TRPM8 channels. To provide direct evidence for this activity, derivatives 21 and 12 were tested in single HEK-293 cells transiently expressing the rat TRPM8 isoform by patch-clamp recordings using a 100-msec voltage ramp ranging from -100 mV to +100 mV delivered every 4 sec. Perfusion with 500 µM menthol activated a large, strongly outwardly-rectifying (I +80 mV /I -80 mV of 90±25; n=39) reversing at a potential near 0 mV (-1.3±0.7 mV; n=10) ( Figures 3A and 3B ). No currents were activated when menthol was perfused on non-transfected cells (0 pA/pF at +80 mV; n=4; data not shown). The dose-response curve at +80 mV of menthol-evoked currents ( Figure 3C ) showed an EC 50 of 75±4 µM, a value close to those for rat 30 and mouse isoforms. Figure 3F ). Notably, the presence of the 1-methyl-4-phenoxybenzene group in this derivative (Scheme 2) appears to be crucial for TRPM8 activation, as the derivative 11 which carries an isoquinoline group showed no agonist activity (0 pA/pF at +80 mV; n=4; data not shown), as also suggest by fluorescence assay ( Figure 1A ). To investigate possible antagonistic effects exerted by the newly-synthesized compounds, we investigated their ability to inhibit menthol-evoked responses. As previously reported, the canonical TRPM8 antagonist BCTC (3 µM) produced a fast and complete inhibition of menthol-gated TRPM8 currents, which largely recovered after drug washout ( Figures 4A and 4B) . 33 Similarly, perfusion of the same concentration of derivative 12, produced a complete inhibition of menthol-induced TRPM8 currents measured at +80 mV ( Figures. 4C and 4D) , with kinetics slower than that observed for BCTC.
This block appears concentration-dependent, with an IC 50 of 367±24 nM (n=3-9;), a value slightly lower than that reported for BCTC (475 nM) 33 . These effects were largely reversible upon drug washout ( Figure 3C ), although with much slower kinetics when compared to those observed for BCTC. 
Molecular modeling and structural rationale
In a recent paper, Taberner et al. reported the central role of S6-TRP box linker (amino acids 980-992 in rat TRPM8) in the gating mechanism of TRPM8 channel. 34 As shown by their homology models based on the experimentally solved structures of TRPV1, the conformational changes in the voltage sensors by activating stimuli could be associated to a widening of the S6 C-end, which in turn might disrupts the intersubunit interactions in the region of Tyr981, thus favoring channel opening. 35 We ran a series of simulations to investigate whether a TRPM8 monomer was able to bind the newly-synthesized small molecules and to test the influence of this binding on the conformation of the functional 980-992 region. We ran SiteMap 36 calculations on the whole monomer to detect potential binding sites. The best site identified (BP1 - Figure S1 ), has a volume of 791 Å and a site score of On the other hand, the antagonist model accounts for the interaction with Ile701, Leu751, Leu697, Leu843 (R1), Glu1004 (P1/D1), Val800 (H1), Arg1008 (R2) and Tyr754 (R1/R2) ( Figure 6B ). The two pharmacophore models might help to understand which chemical features are required to endow a ligand with agonist or antagonist capabilities. Despite binding to the same site, the two models present in fact substantial differences that may cause the observed differences induced in TRPM8
conformation. All the agonists reported in this paper fit, at least in part, the agonist model. All of them in fact place correctly D1/P1, D2 (compounds 4, 5, 6, 7, 15, and 21) and H1 features (21) . R1 location is always occupied by a large substituent claiming the space of Arg1008 side chain and in same cases this moiety engages in HB with the Arg1008 backbone. By contrast R2 antagonist feature has to be, when present, a small substituent that does not occupy the Arg1008 room. H1 is probably the feature that boosts the activity of 21, since it is the only one that perfectly fits it. Regarding the antagonists model, H1, P1 and D1 seem to be the mandatory feature for exerting antagonism (compounds 12 and both conformers of 22), while R1 could boost activity by π-π interaction with Tyr754, and a relatively small R2 substituent could be engaged, by its π cloud, in interaction with Tyr754 and the positively charged Arg1008 side chain, improving its antagonist capabilities. Looking at the fittings of the tryptamine-based agonists and antagonists sets, it seems that the mandatory features to exert agonism are H2, P1, D1 and D2, while on the other side H1, P1 and D1 are necessary for the antagonists (see Table S1 ).
Conclusions
Here we report the synthesis and pharmacological evaluation of a small library based on the tryptamine scaffold designed as TRPM8 ion channel modulators. Two of the synthesized derivatives, compounds 12 and 21, showed to be efficient and potent TRPM8 antagonist and agonist, respectively. In fact, 12
produced a complete inhibition of menthol-induced TRPM8 currents with a higher potency than that reported for the well-known TRPM8 antagonist BCTC. Meanwhile the agonist 21 showed a significantly higher potency and efficacy than menthol. In addition, compound 12 showed unremarkable activity on TRPV1 and TRPA1 at different concentrations while the agonist 21 behaved as an antagonist on both TRPV1 and TRPA1 receptors at high concentration.
Computational studies allowed us to hypothesize a binding site and two pharmacophore prototypes for this series of tryptamine-based TRPM8 modulators. The proposed structural model identifies the same binding site for agonist and antagonist, but two binding modes differing in the "interaction network".
Since structural models have to be used with caution, further investigations are needed to confirm the structural hypothesis. The results of this study provide valuable information for the future design of new and specific TRPM8 modulators that could be useful in the treatment of different diseases involving a deregulation of this ion channel.
Experimental section
General. Reagents, starting materials, and solvents were purchased from Sigma-Aldrich ( 
Synthesis of 1-(Iodomethyl)-4-phenylbenzene intermediate (III).
To one equivalent of biphenyl-4-carboxylic acid (I) dissolved in dry THF was added portionwise 
1-(Biphenyl-4-ylmethyl)-3-(2-bromoethyl)-1H-indole (3).
Prepared from intermediate III and 3-(2-bromoethyl)indole as described above. 
General procedure for the synthesis of derivatives 4-12.
One equivalent of 3-(2-bromoethyl)indole (1) or intermediate 2 or 3 was dissolved in THF and 1.5 eq of the proper amine, 1.5 eq of TEA, 1.5 eq of NaI and 0.3 eq of (CH 3 COO) 2 Pd were added to this solution (Scheme I). The reaction was conducted under W, at 100°C, for 20 minutes. The resulting mixture was filtered through Celite, dried in vacuo and reconstituted in DCM. The organic phase was washed with water (3 x 50 mL), dried over anhydrous Na 2 SO 4 , filtered, concentrated and purified by column chromatography using DCM/MeOH as mobile phase.
N-(4-Methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (4)
Synthesized starting from 3 and 4-methoxybenzylamine, yield 71%. 1 
N-(4-Chlorobenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (5)
Synthesized starting from 3 and 4-chlorobenzylamine, yield 69%. 
2-([1,1'-Biphenyl]-4-yl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)ethanamine (6).
Synthesized starting from 3 and 2-(4-biphenyl)ethylamine, yield 65%. 1 
2-(1-([1,1'-Biphenyl]-4-ylmethyl)-1H-indol-3-yl)-N-(3,4-dimethoxyphenethyl)ethanamine (7).
Synthesized starting from 3 and 3,4-dimethoxyphenthylamine, yield 75%. 1 
N-[2-(1H-Indol-3-yl)ethyl]naphthalen-1-amine (8).
Synthesized starting from 1 and 1-naphtalenlamine, yield 55%. 1 
N-[2-(1H-Indol-3-yl)ethyl]naphthalen-2-amine (9).
Synthesized starting from 1 and 2-naphtalenlamine, yield 58%. 1 
2-(1H-Indol-3-yl)-N-(quinolin-5-yl-methyl)ethanamine (10).
Synthesized starting from 1 and 5-aminoquinoline, yield 63%. 1 
2-(1H-Indol-3-yl)-N-(isoquinolin-5-ylmethyl)ethanamine (11).
Synthesized starting from 1 and 5-aminoisoquinoline, yield 67%. 1 
N,N-Dibenzyl-2-(1H-indol-3-yl)ethanamine (12).
Synthesized starting from 1 and dibenzylamine, yield 73%. 1 
N-[(1,2,3,4,Tetrahydronaphthalen-1-yl)methyl]-2-(1H-indol-3-yl)ethanamine (14).
A 10 mL sealable flask, equipped with a stir bar, was charged with 1 eq of tosylate VI, and 2.6 eq of tryptamine (13, Scheme 3), dissolved in THF. The flask was sealed, heated to 60-70°C, and allowed to stir at that temperature overnight. The resulting slurry was cooled to room temperature, added with DCM and washed with brine. The organic layer solvents was dried over Na 2 SO 4 , filtered and evaporated under vacuum. The resulting mixture was separated by silica gel chromatography using DCM/MeOH 9/1 as eluent. 
General procedure for the synthesis of derivatives (15-22).
Tryptamine (1.0 eq) was dissolved in a solution of DCM:CH 3 COOH (5:1 v/v) at room temperature. To this solution 2.0 equivalents of the proper aldheyde were added and the mixture was warmed to reflux for 1.5h. Then, 1.8 equivalents of sodium triacetoxyborohydride were added portionwise and the mixture was allowed to reflux for further 3-5h. After cooling to room temperature, NaOH 1N was added. The organic phase was separated and extracted one more time with the alkaline solution. Then it was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The crude products were purified by column chromatography using mixtures of DCM/MeOH as eluent.
2-(1H-Indol-3-yl)-N-(naphthalen-1-ylmethyl)ethanamine (15).
Synthesized starting from 13 and 1-naphthaldehyde, yield 75%. 1 
2-(1H-Indol-3-yl)-N-[(7-methoxynaphthalen-1-yl)methyl]ethanamine (16).
Synthesized starting from 13 and 2-methoxy-1-naphthaldehyde, yield 63%. 1 
1-[(2-(1H-Indol-3-yl)ethyl)amino]methyl]naphthalen-2-ol (17).
Synthesized starting from 13 and 2-hydroxy-1-naphthaldehyde, yield 51%. 1 
2-(1H-Indol-3-yl)-N-[(10-methylanthracen-9-yl)methyl]ethanamine (18).
Synthesized starting from 13 and 10-methyl-9-anthracenecarbaldehyde, yield 58%. 1 
5[(2-(1H-Indol-3-yl)ethylamino)methyl]-2-methoxyphenol (19).
Synthesized starting from 13 and vanillin, yield 58%. 1 
N-(3,4-Dimethoxybenzyl)-2-(1H-indol-3-yl)ethanamine (20).
Synthesized starting from 13 and 3,4-dimethoxybenzaldehyde, yield 72%. 1 
2-(1H-Indol-3-yl)-N-(4-phenoxybenzyl)ethanamine (21)
Synthesized starting from 13 and 4-phenoxybenzaldehyde, yield 83%. 1 
N-Methyl-2-(1-methyl-1H-indol-3-yl)-N-(4-phenoxybenzyl)ethanamine (22)
Compound 21 (1 eq) was dissolved in a mixture of anhydrous DCM/DMF (2/1 v/v) under magnetic stirring and the temperature was set to 0°C. To this solution, 3 equivalents of NaH were added portionwise and the mixture was allowed to react for 30 minutes. Then, 3 equivalents of methyl iodide in dry DCM were added dropwise and the reaction was warmed to room temperature and maintained under stirring for further 12h. Then, reaction was quenched by 10% aqueous solution of citric acid and washed with brine. Organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered and evaporated in vacuo. Crude product was purified by column chromatography using DCM/MeOH 
Pharmacology

Cell culture and transfections
For fluorescence assays, cells stably expressing TRP channels (SH-SY5Y for TRPV1, HEK for TRPM8 and IMR90 for TRPA1) were cultured in a monolayer at 37ºC in a humidified atmosphere of 5% CO 2 in Earle's minimum essential medium with Earle's salts supplemented with 10% fetal calf serum,1% nonessential amino acids, 2 mM L-glutamine, 100 µg streptomycin/ml, 100 U penicillin/ml, and the correspondent antibiotic for each stable cell line (0.4 µg/ml puromycin for Sh-SY5Y and 400 g/ml G418 for HEK-CR1).
For electrophysiological experiments, HEK293 cells were grown in 100-mm plastic Petri dishes in Dulbecco's modified Eagle medium containing 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 U/ml) in a humidified atmosphere at 37°C with 5% CO 2 . The cells were seeded on and Lys were adjusted to match a pH of 7.4. The structure was finally submitted to a restrained minimization (OPLS2005 force field) 41 that was stopped when RMSD of heavy atoms reached 0.30 Å.
Ligands were sketched using the Maestro 42 interface and 3D coordinates were generated using LigPrep 43 Ionization/tautomeric states were predicted for a pH range of 7±1 using Epik. 40 The most populated ionization state for each ligand was retained.
Sitemap calculations
All TRPM8 atoms were considered in the identification the top ranking potential binding sites. Each site was required to have at least 5 site points and was cropped at 4 Å from the nearest site point. The definition of hydrophobicity was set to "restrictive".
Molecular docking
Docking of 12 and 21 was performed using Glide SP [44] [45] [46] and XP 47 in a stepwise manner. The docking spaces was defined as as a 50Å 3 cubic box, while the diameter midpoint of docked ligands was required to remain within a smaller, nested 30Å 3 cubic box centered on the centroid of BP1 site points. Receptor OH and SH groups were set free to rotate. Two docking grids were used for SP and XP docking, differing for the scaling of vdW radii for non polar receptor atoms only. For SP a coefficient of 0.85 was used, while no scaling was used for XP.
At most ten poses for each ligand were retrieved from the SP docking, discarding as duplicates poses that showed both RMS deviation less than 1.5Å and maximum atomic displacement less than 2.0Å.
These poses were then refined, rescored and minimized using Glide XP. The best scoring XP pose for each ligand was then retained for the MD simulations.
Molecular dynamics simulation
MD simulations of TRPM8/12 and TRPM8/21 complexes were set and run using Desmond MD system [48] [49] [50] . The simulated environment was built using the system builder utility, with the structures 
Pharmacophore modeling
Docking/MD predicted bound conformations were used to manually build the pharmacophore models summarizing the chemical feature of tryptamine based agonists and antagonists. Models were built using the software Phase. [51] [52] [53] Features and their coordinates were automatically detected using the ligand-based option of Phase and were then edited in freestyle modes according to the ligand-protein interaction detected by the Simulation Interaction diagram tool. In particular, H1 and H2 features were previously detected as aromatic features, but were changed to hydrophobic since during the MD trajectories they interacted with non aromatic hydrophobic residues only. For the same reason, the R3 feature of the antagonist model was changed to H1. After the model generation and refinement phase was used to evaluate the fitness of the tryptamine based agonists and antagonists on the two models as reported in Table S1 .
Statistical analysis
Data are expressed as mean ± SEM. Statistically significant differences were evaluated with the Student t test or with ANOVA followed by the Student-Newman-Keuls test, with the threshold set at p<0.05.
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